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Abstract
Background: Individuals infected by HIV are at an increased risk for developing non-Hodgkin’s lymphomas (AIDS-NHL). In
the highly active antiretroviral therapy (HAART) era, there has been a significant decline in the incidence of AIDS-associated
primary central nervous system lymphoma (PCNSL). However, only a modest decrease in incidence has been reported for
other AIDS-NHL subtypes. Thus, AIDS-NHLs remain a significant cause of morbidity and mortality in HIV infected individuals.
Recently, much attention has been directed toward the role of miRNAs in cancer, including NHL. Several miRNAs, including
those encoded by the miR-17-92 polycistron, have been shown to play significant roles in B cell tumorigenesis. However,
the role of miRNAs in NHL in the setting of HIV infection has not been defined.
Methodology/Principal Findings: We used quantitative realtime PCR to assess the expression of miRNAs from three
different paralog clusters, miR-17-92, miR-106a-363, and miR-106b-25 in 24 cases of AIDS-NHLs representing four tumor
types, Burkitt’s lymphoma (BL, n=6), diffuse large B-cell lymphoma (DLBCL, n=8), primary central nervous system
lymphoma (PCNSL, n=5), and primary effusion lymphoma (PEL, n=5). We also used microarray analysis to identify a
differentiation specific miRNA signature of naı ¨ve, germinal center, and memory B cell subsets from tonsils (n=4). miRNAs
from the miR-17-92 paralog clusters were upregulated by B cells, specifically during the GC differentiation stage. We also
found overexpression of these miRNA clusters in all four AIDS-NHL subtypes. Finally, we also show that select miRNAs from
these clusters (miR-17, miR-106a, and miR-106b) inhibited p21 in AIDS-BL and DLBCL cases, thus providing a mechanistic
role for these miRNAs in AIDS-NHL pathogenesis.
Conclusion: Dysregulation of miR-17-92 paralog clusters is a common feature of AIDS-associated NHLs.
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Introduction
The risk for developing non-Hodgkin lymphoma (NHL) is
greatly increased in those persons who are living with HIV
infection. In fact, NHL in the setting of HIV infection, is an AIDS
defining condition. AIDS-related NHL comprise a heterogenous
group of B cell lymphomas that includes Burkitt’s lymphoma (BL),
diffuse large B-cell lymphoma (DLBCL), primary central nervous
system lymphoma (PCNSL), primary effusion lymphoma (PEL)
and plasmablastic lymphomas (PBL) [1]. In the post-HAART era
there has been a dramatic reduction in the incidence of PCNSL,
however, only a modest decrease has been reported for other NHL
subtypes [2,3]. Various factors are believed to contribute to the
pathogenesis of AIDS-NHL, including immune deficiency,
chronic B cell stimulation, cytokine dysregulation, genetic lesions
involving oncogenes or tumor suppressor genes, and the presence
of Epstein-Barr virus (EBV) and/or Kaposi’s sarcoma-associated
herpesvirus/human herpesvirus-8 (KSHV/HHV-8) [4].
microRNAs (miRNAs) are a class of endogenous small non-
coding RNAs (,21–23 nt) that bind to the 39 untranslated region
(UTR) of mRNAs and mediate cleavage or cause translational
inhibition [5]. miRNAs are conserved and expressed across diverse
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human miRNAs (Sanger miRBase v15) have been identified in
humans and they regulate critical cellular processes including
proliferation, differentiation, metabolism, cell death/apoptosis and
tumorigenesis (reviewed in [7]). miRNAs can also act as tumor
suppressors or oncogenes and have been shown to be deregulated
in almost every tumor type studied. Furthermore, miRNA
profiling has revealed tumor specific signatures with diagnostic,
prognostic, and therapeutic implications [7].
It is becoming increasingly clear that miRNAs play a role in B
cell tumorigenesis. miR-16-1/miR-15a cluster located at 13q14, is
frequently deleted or downregulated in chronic lymphocytic
leukemia (CLL), leading to upregulation of its target protein
Bcl2 [8]. Loss of miR-16-1 binding sites due to translocation of
CCND1 (cyclin D1) and truncation of its 39UTR contributes to its
overexpression in mantle cell lymphomas (MCL) [9]. Additionally,
miR-155, encoded by exon 3 of the non-coding BIC (B cell
integration cluster) transcript [10], is upregulated in Hodgkin’s
lymphoma [11,12], primary mediastinal B cell lymphomas [11],
and DLBCL [11,13], but not in BL [14]. Accordingly, transgenic
overexpression of miR-155 in mouse model leads to development
of pre-B cell leukemia and ultimately high grade lymphomas [15].
Even a B cell tropic oncogenic herpesvirus, EBV, has been shown
to upregulate miR-155 [16], whereas HHV-8 encodes miR-K12-
11, which is an ortholog of human miR-155 [17,18].
Several studies have suggested an oncogenic role for the miR-
17-92 cluster (which encodes seven miRNAs: miR-17-5p, miR-17-
3p, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92-1) in B
cell lymphomagenesis. Chromosomal amplification at 13q31-q32
leads to overexpression of the miR-17-92 cluster encoded by the
Chromosome 13 open reading frame 25 (C13orf25) gene in several B cell
lymphomas, including DLBCL [19–21], follicular lymphoma
[21,22], mantle cell lymphoma [23], and primary cutaneous B-
cell lymphomas [24]. Consistent with its proposed oncogenic role,
enforced expression of the miR-17-19b polycistron greatly
accelerated lymphoma onset in mouse model of lymphoma driven
by c-myc expression [21]. miR-17-92 is also overexpressed in MLL
(mixed lineage leukemia)-rearranged acute myeloid leukemia
(AML) and acute lymphoblastic leukemia (ALL) [25], and in
CD34+ chronic myeloid leukemia (CML) [26]. Overexpression of
the miR-17-92 cluster has been shown to enhance proliferation in
CML lines [26], BL and DLBCL lines [27], and to play a role in a
mouse model of MLL-leukemia [28], by targeting the cell cycle
inhibitor p21. In the c-myc induced B-cell lymphoma mouse model,
miR-19a and miR-19b were shown to be largely sufficient for the
oncogenic property of miR-17-92 cluster, operating by targeting
the tumor suppressor PTEN [29]. Finally, miR-17-92 cluster was
also shown to target the proapoptotic protein Bim, in a mouse
model, with overexpression [30] or deletion of the cluster [31].
Even though HIV does not directly infect B cells, HIV
infection is associated with a marked increase in risk for NHL
[32]. In contrast to NHLs that develop in immunocompetent
hosts, AIDS-NHLs typically exhibit a more aggressive clinical
phenotype with a predilection for extranodal sites [1]. The role of
miRNAs in B cell lymphomas in the setting of HIV/AIDS and
immunodeficiency is not well understood. Here we asked if
miRNA overexpression from the miR-17-92 cluster, as well as its
two other paralogs (miR-106a-363, and miR-106b-25), is also a
common feature of B cell lymphomas in the setting of HIV
infection and AIDS. Using quantitative real-time PCR (q-PCR),
we assessed the expression of miRNAs from these three paralog
clusters in 24 cases of AIDS-NHLs representing four tumor types:
BL (n=6), DLBCL (n=8), PCNSL (n=5), and PEL (n=5). Also,
in order to establish a differentiation specific miRNA profile, we
compared the miRNA profile of three tonsillar B cell subsets:
naı ¨ve, germinal center (GC), and memory. Our results demon-
strate that miRNAs from the miR-17-92 paralog clusters are
selectively upregulated by B cells during the GC stage of
differentiation and are also significantly overexpressed in all of
the AIDS-NHL types we examined. Additionally, we show that
miR-17, miR-106a, and miR-106b inhibit p21 expression in
AIDS-BL and DLBCL, thus supporting an oncogenic role for
these miRNAs in AIDS-NHL pathogenesis.
Materials and Methods
Ethics statement
An application for the use of all anonymized patient samples,
including tonsils, peripheral blood, and archived tissues utilized in
this study was submitted to the UCLA Institutional Review Board
(IRB), which concluded that these activities did not involve human
subjects, and therefore did not require IRB review or certification,
or exemption from IRB review. Tonsil tissue specimens (excess
surgical pathology materials) were obtained from the Translational
Pathology Core Laboratory (TPCL) of the University of California
Los Angeles (UCLA) Medical Center. Written consent was not
obtained from those subjects from whom the tonsils specimens
were obtained. The TPCL has approval from the UCLA IRB
confirming that patient consent is not needed when the human
tissue samples are provided to investigators in a completely
anonymized fashion. Peripheral blood mononuclear cells (PBMC)
from healthy donors were provided by the Virology Core of the
UCLA AIDS Institute, which obtained these discarded specimens
from the UCLA Blood and Platelet center. These PBMC were
obtained with written informed consent, and the Virology Core
has IRB approval for obtaining and distributing these specimens.
The AIDS & Cancer Specimen Resource (ACSR), which provided
primary AIDS-NHL samples, obtained written informed consent
from all participants and have approved IRB protocols for this
study at each collecting sites.
Cell lines, tissues, and clinical specimens
The AIDS-Burkitt’s cell line (2F7, ATCC CRL-10237) and a
DLBCL line (Toledo, ATCC CRL-2631) were cultured in RPMI
1640 (Cellgro, Manassas, VA) supplemented with 10% fetal calf
serum (Atlanta Biologicals, Lawrenceville, GA), 1% L-glutamine
(Cellgro, VA), and 1% penicillin/streptomycin (Cellgro, VA).
293T cells (ATCC CRL-11268) were cultured similarly, but in
DMEM (Invitrogen, Carlsbad, CA). All three cell lines used in
this study, 2F7, Toledo, and 293T were obtained from the ATCC
(www.atcc.org). PBMC and tonsil tissue specimens were provided
without any indirect or direct patient identifiers and were
completely anonymized. Twenty-four primary B cell tumors
from HIV infected individuals were obtained from the AIDS &
Cancer Specimen Resource (ACSR) repository (Table S1). Snap
frozen specimens were obtained for six Burkitt’s lymphomas,
eight DLBCL, and two PEL. 3610 mM sections from FFPE
blocks were obtained for one DLBCL, five CNS and three PEL
tumors.
Isolation of tonsillar B cell subsets
Tonsils, obtained from four different donors, were minced and
the mononuclear cell population was isolated from the buffy layer
following centrifugation in Ficoll-paque (GE Healthcare, Uppsala,
Sweden). B cells were isolated from this population using CD19+
immunomagnetic dynabeads (Invitrogen, Carlsbad, CA). The
CD19+ immunomagnetic beads were removed using CD19
DETACHaBEAD (Invitrogen, Carlsbad, CA). These CD19+ cells
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and IgD-FITC (BD Pharmingen, San Jose, CA) antibodies.
Following staining, the cells were separated into naı ¨ve (IgD+,
CD382), germinal center (IgD2, CD38+), and memory (IgD2,
CD382) populations using the method described by Pascual V
et al. [33]. Fluorescence-activated cell sorting (FACS) was
performed using FACSAriaII high-speed cell sorter (Becton
Dickinson) housed at the UCLA Jonsson Comprehensive Cancer
Center (JCCC) and Center for AIDS Research Flow Cytometry
Core Facility.
Total RNA isolation
Total RNA from tonsillar B cell subsets, and cell lines were
extracted using mirVana miRNA isolation kit (Ambion, Austin,
TX); from snap-frozen tumor specimen using mirVana PARIS kit
(Ambion, Austin, TX); and from FFPE samples using RecoverAll
total nucleic acid isolation kit (Ambion, Austin, TX). All extraction
was done following the manufacturer’s suggested protocol.
MicroRNA expression profiling
Cellular and viral miRNAs were profiled at the UCLA Clinical
Microarray Core facility using miRCURY
TM LNA microRNA
array v.11.0 (Exiqon, Vedbaek, Denmark). Briefly, up to 0.5 mg
total RNA was Hy3 labeled and hybridized overnight to the
microRNA array. The following day, the array slides were washed
and scanned using GenePix personal 4100A scanner (Axon
Instruments, Union City, CA). After data quality evaluation and
filtration to remove miRNAs with signals below baseline (mean of
negative control+3 standard deviation), the signal was normalized
using a factor derived from the mean of the signal intensity of
several house-keeping small RNAs (U6, snRNAs, snoRNAs and
5SRNAs). This normalized data was then log2-transformed and
analyzed using the MultiExperiment Viewer Software v.4 (http://
mev.tm4.org) [34]. miRNA expression was ranked by standard
deviation across samples and only the top 50% of variably
expressed miRNAs were selected for further analysis. Unsuper-
vised hierarchical clustering was done using Euclidean distance
and average linkage clustering. This microarray data is available
through the Gene Expression Omnibus (GEO) database (http://
www.ncbi.nlm.nih.gov/geo) using accession number GSE27504.
MicroRNA target prediction
Predicted gene targets of miRNAs were obtained from the
TargetScan [35] website: http://www.targetscan.org.
Real-time quantitative PCR
Mature miRNAs miR-17, miR-18a, miR-19a, miR-106a, and
miR-106b were first converted to cDNAs using TaqMan
microRNA RT kit and microRNA specific primers (Applied
Biosystems, Foster City, CA) followed by quantitative PCR using
TaqMan microRNA Assay (Applied Biosystems, Foster City, CA).
Sequences for all miRNAs that are targeted by these assays can be
found at: http://www.appliedbiosystems.com/. miRNA levels
were normalized to the expression of small nucleolar RNA,
RNU48. Relative mRNA levels of p21 were quantified using the
one step TaqMan RNA to CT reagent (Applied Biosystems, Foster
City, CA) in combination with gene specific primers/probe from
TaqMan gene expression assay (Applied Biosystems, Foster City,
CA). All mRNA expression values were normalized to b-actin
levels. CT values were obtained using ABI 7300 Real-Time
machine (Applied Biosystems, Foster City, CA). The relative
amount of miRNA (or mRNA) was calculated as 2
2dCT (where
dCT=CT gene(or miRNA)2CT endogenous control) and expressed as a
% of the endogenous control. The efficiency of PCR was
calculated from the slope of the standard curve and was within
the range of 90–110%.
Cell transfection and proliferation assay
AIDS-BL line 2F7 and DLBCL line Toledo were transfected
using Amaxa nucleofector reagent V (Lonza, Switzerland) using a
nucleofector device (Lonza, Switzerland). Briefly, 5610
6 cells were
resuspended in 100 uL of reagent V with synthetic miRNA
precursors or anti-miRNAs (Ambion, Austin, TX) at a concen-
tration of 200 nM. The cells were then electroporated using pre-
set protocol O-006. Transfected cells were cultured in T25 flasks
and cell proliferation was assessed by using XTT Cell Proliferation
Kit II (Roche, Mannheim, Germany). Briefly, 100 mL aliquots of
cell culture were incubated for 4 hours with a 50:1 mixture of
XTT labeling reagent:electron-coupling reagent. Metabolization
of XTT to formazan salt by viable cells was measured as
absorbance value at 480 nm with 650 nm being the reference.
Western blots
Cells were washed with 16 PBS and resuspended in RIPA
buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholate, 1 mM EDTA, 0.1% SDS) supple-
mented with 16Halt protease inhibitor cocktail (Pierce, Rockford,
IL) and 20 mM MG-132 (VWR, West Chester, PA). The cells were
iced for 10 minutes, sonicated briefly, vortexed and centrifuged.
The supernatant was collected and the protein quantified using
BCA assay (Pierce, Rockford, IL). The cell lysates were run on 4–
20% Tris-HCL ready gels (Biorad, Hercules, CA), transferred for
1.5 hrs on to Immobolin-P
sq membrane (Millipore, Billerica, MA)
and blocked using 5% non-fat dry milk before incubating
overnight in primary antibodies. Following washing, HRP
conjugated secondary antibodies were added for 1 hour and the
signal detected using Supersignal West Pico substrate (Pierce,
Rockford, IL). The following antibodies were used at the
concentration recommended by the manufacturers: p21
(DCS60), Rb (4H1), p53 (1C12), Bcl2 (#2872), CDK4
(DCS156), CDK6 (DCS83), and Bim (Cell Signaling Technology,
Boston, MA); p53 (DO-7) (Dako, Carpinteria, CA) and b-actin
(AC-15) from Sigma (St Louis, MO). Kodak 1D 3.6 Scientific
Imaging Software was used to quantify protein band intensity. For
each gene the normalized expression was calculated as: gene
signal/b-actin signal where signal=mean pixel intensity6area of
band.
39UTR cloning and luciferase assays
The 39UTR of CDKN1A was obtained by PCR of its cDNA
clone (OriGene, Rockville, MD). Spe I and Mlu I restriction sites
was introduced at its ends and then cloned into pMIR-REPORT
vector (Ambion, Austin, TX) downstream of firefly luciferase.
Additionally, to disrupt the miRNA:39UTR interaction, two base
pairs in the middle of the miRNA recognition seed sequence were
mutated using the QuickChange II XL site-directed mutagenesis
kit (Stratagene, La Jolla, CA). All inserts and mutations were
verified by sequencing.
The following primers were used (restriction sites are italicized,
mutations are in bold): CDKN1A 39UTR Fw GCTGACTAGT-
CACAGGAAGCCTGCAGTCCT, Rv CGACACGCGTGAG-
CACCTGCTGTATATTCAGC; CDKN1A Fw (CT to GA
mutation, site #1, nucleotide 468–474).
TTTGAGAAGTAAACAGATGGCAGATTGAAGGGGCC-
TCACCGAGTG and reverse compliment; CDKN1A Fw (CT to
GA mutation in site#2, nucleotide1148–1154).
miR-17-92 Overexpression in AIDS-Related NHL
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CGGAACAAGG and reverse compliment.
Briefly, 293T cells were seeded at a density of 50,000 cells/well
in 24 well plates a day before transfection in antibiotic-free media.
20 ng of the plasmids with the 39UTR of the gene of interest
cloned into the pMIR-REPORT were co-transfected with 10 ng
of renilla luciferase expressing vector pRL-SV40 (Promega,
Madison, WI) and 100 nM precursor/antimiR miRNA oligos
(Ambion, Foster City, CA) using lipofectamine-2000 reagent
(Invitrogen, Carlsbad, CA). 24 hours post transfection, cells were
washed with PBS and the amount of firefly and renilla luciferase
was quantified using dual-luciferase reporter assay system
(Promega, Madison, WI) using a BD monolight 2010 instrument
(BD, New Jersey). All samples were assayed in triplicates and
independently repeated three times.
Statistical analysis
Comparison between groups was done by t-test or Mann-
Whitney U test using the GraphPad Prism 5 software. p,0.05 was
considered statistically significant. Error bars represent standard
deviation.
Results
miRNAs are differentially expressed in tonsillar B cell
subsets
Most cancers of mature B cells, including many AIDS-NHL, are
thought to arise from neoplastic transformation during the GC
transition. Hence, in order to establish a miRNA signature
associated with normal B cell differentiation and maturation we
first looked at the miRNA expression pattern of tonsillar B cell
subsets. Mature B cells isolated from tonsils were separated by flow
cytometry into three subsets: naı ¨ve (IgD+, CD382), germinal
center (GC) (IgD2, CD38+), and memory (IgD2, CD382)B
cells. miRNA expression in these B cell subsets was profiled using
Exiqon’s miRCURY
TM LNA microRNA microarray. Unsuper-
vised hierarchical clustering of miRNAs from these subsets
produced a heat map, which demonstrates that these B cell
subsets cluster distinctly from each other (Figure 1A). Out of the 48
miRNAs differentially regulated between the naı ¨ve to GC
transition, 33 miRNAs were downregulated and 15 miRNAs were
distinctly upregulated. Several miRNAs including miR-30, miR-
150, miR-222, miR-223, and the let-7 family of miRNAs (let-7a,
let-7c, let-7e, let-7f, let-7g, and let-7i) were downregulated by the
naı ¨ve B cell subset upon GC entry, and remained at baseline levels
even in the memory subsets. Among those 15 GC upregulated
miRNAs, eight miRNAs (miR-17, miR-18a, miR-18b, miR-19a,
miR-20a, miR-20b, miR106a, miR-106b) are members of the
miRNA paralog clusters miR-17-92, miR106a-363, and miR-
106b-25, located at three different chromosomal sites (Figure 1B).
Six miRNAs (miR-1280, miR-1826, miR-1285, miR-933, miR-
1264, miR-146b-5p) were also found to be specifically upregulated
in memory subsets. Overall, tonsillar B cell subsets show a
remarkable level of coregulation of miRNAs as groups in an
asymmetrical fashion, especially that of the miR-17-92 paralog
clusters (indicated by arrows in Figure 1A), which is GC subset
specific.
miRNAs from the miR-17-92 paralog clusters are
overexpressed in AIDS-NHLs
Our study of AIDS-NHL includes mature B cell lymphoma
types derived from GC or post-GC B cells. BL and DLBCL
display GC B cell markers. PCNSL are DLBCL with immuno-
blastic features and EBV LMP1 expression. Both PCNSL and
PEL display post-GC markers. Based on this information and our
data showing specific upregulation of the miR-17-92 paralog
clusters in GC subsets, we used quantitative realtime PCR (q-
PCR) to assess the level of several miRNAs encoded by this cluster
in 24 primary AIDS-NHL samples (Table S1). The expression of
miRNAs was normalized to the expression of the small nucleolar
RNA, RNU48, and shown as relative miRNA levels (Table S2).
We assessed the expression of miR-17, miR-106a, miR-106b,
miR-18a, and miR-19a in AIDS-NHL subtypes, BL (n=5),
DLBCL (n=8), PCNSL (n=5), PEL (n=5) and compared it to
control CD19+ B cells isolated from PBMC and tonsils (Figure 2
A–E). In the control samples, as expected, there was a clear (but
nonsignificant) elevation of these miRNAs in tonsillar B cells
compared to peripheral B cells. However, all of these miRNAs
were significantly overexpressed in the lymphoma samples
(*p,0.05; **p,0.01) when compared to non-neoplastic B cell
controls (both, PBMC and tonsil derived), except for in three
instances: miR-106b in PEL (p=0.085), miR-18a in PCNS
(p=0.0651), and miR-19a in PEL (p=0.0635) (Figure 2 A–E).
Nonetheless, even in the nonsignificant cases, the mean (data not
shown) and median of these miRNA expressions was clearly
higher than in the controls. Overall, our results show that miRNAs
from the miR-17-92 paralog clusters—miR-17, miR-106a, miR-
106b, miR-18a, and miR-19a are overexpressed in AIDS-NHLs.
miR-17 family members target p21/CDKN1A
Given the overexpression of miR-17-92 cluster miRNAs in
AIDS-NHL, we next focused on potential molecular targets for
these miRNAs. miRNAs target mRNAs with a specificity
primarily determined by Watson-Crick base-pairing of the
miRNA seed region (nucleotides 2 to 7/8) to the 39UTR of target
mRNAs. Hence, miRNAs sharing similar seed sequences are
grouped as families and they are predicted to have similar targets.
As such, we selected miR-17, miR-106a, and miR-106b which all
share the seed sequence AAAGUG, for further analysis.
TargetScan (http://www.targetscan.org) predicts 2 binding sites
for this family of miRNAs in the 39UTR of the key cell cycle
inhibitor p21 (Figure 3A). We cloned the 39UTR of p21 with, or
without, mutation in both seed region recognition sites down-
stream of the firefly luciferase gene. This construct was then co-
transfected into 293T cells with renilla luciferase (as transfection
control) and precursor miRNAs. For bona fide miRNA targets, it
is expected that miRNA:mRNA interaction will lead to suppres-
sion of firefly luciferase activity. miR-106a and miR-106b
significantly inhibited luciferase activity in unmodified p21
39UTR when compared to the mutant p21 39UTR (Figure 3B).
In order to shown that this miRNA:mRNA interaction also takes
place in a physiological milieu in B cells, we transfected antimiRs
to specifically block the endogenous miR-17, miR-106a, and miR-
106b in Toledo cells. Functionally blocking a miRNA should lead
to decreased binding of the miRNA to its target mRNA, and
Figure 1. miRNA profiling of tonsillar B cell subsets. (A) Unsupervised hierarchical clustering of miRNAs from naı ¨ve (N) (IgD+, CD382),
germinal center (GC) (IgD2, CD38+), and memory (M) (IgD2, CD382) cells isolated from CD19+ tonsillar B cells. Arrows point to miRNAs that are
members of the miR-17-92 paralog clusters. Red denotes overexpression; green, downregulation; and black, median expression. (B) Schematic
representation of the three paralogous cluster showing genomic location and the relative position of individual miRNAs (figure modified from Tanzer
A et al. [61]).
doi:10.1371/journal.pone.0020781.g001
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blocking endogenous miR-106a and miR-106b activity in Toledo
resulted in a 1.4 and 1.6 fold increase in p21 protein levels
respectively (Figure 3C). This increase was also reflected at the
mRNA level with a 1.77 fold increase in p21 mRNA for both
antimiR-106a and antimiR-106b (Figure 3D). However, blocking
endogenous miR-17 did not increase p21 protein level (in fact, a
0.79 fold decrease was noted) (Figure 3C), despite a 1.37 fold
increase in p21 mRNA level (Figure 3D). This suggests that, while
miR-17 has some affinity for p21 mRNA binding, the overall p21
protein expression may be primarily dependent on the presence of
miR-106a and miR-106b, which presumably bind p21 mRNA
with a higher affinity.
Additionally, we also looked at the effect that blocking these
miRNAs have on the expression of other proteins that play a role
in cell survival and proliferation. Inhibition of all three of these
miRNAs had no effect on the levels of Bcl2, but led to increased
levels of Bim (isoform L), and decreased levels of CDK4 and
CDK6 (Figure 3C). Both Bcl2 and Bim regulate apoptosis, albeit
in an opposing manner. Bcl2 is a pro-survival molecule that
inhibits apoptosis while Bim is a proapoptotic molecule. CDK4
and CDK6 promote S phase entry and cell cycle progression by
partnering with cyclin D to phosphorylate the Rb protein. Overall,
these results demonstrate an oncogenic role for miR-17, miR-
106a, and miR-106b by targeting the cell cycle inhibitor p21 and
the proapoptotic Bim protein.
Given that these miRNAs target a cell cycle inhibitor, next we
studied its effect on cellular proliferation. We selected two cell
lines, 2F7 (AIDS-BL) with modest expression and Toledo
(DLBCL), with overexpression, of miR-17, miR-106a, and miR-
106b. Overexpression of synthetic precursors for all three miRNAs
increased cellular proliferation in 2F7 cells by 48 hrs post
transfection (Figure 3E). We also transfected synthetic antimiR-
NAs to functionally block these endogenous miRNAs in Toledo
cells. AntimiR-17 showed no effect in Toledo proliferation,
whereas proliferation was decreased with antimiR-106a and
antimiR-106b by up to 87% and 83% of control proliferation,
respectively (Figure 3F). Thus, miR-17, miR-106a, and miR-106b
accelerate cellular proliferation by targeting the cell cycle inhibitor
p21.
p21 is silenced post-transcriptionally in primary AIDS-
NHL tumors
Finally, we examined p21 protein (Figure 4A) and mRNA
(Figure 4B) expression in primary AIDS-BL and AIDS-DLBCL
cases. p21 mRNA levels in Figure 4B are shown as a percentage of
the housekeeping gene b-actin expression (set to 100). p21 protein
expression was not detected in any of the tumor samples, despite
p21 mRNA levels approaching up to 20% of b-actin expression.
We also looked at the expression of p53 in these tumors using the
anti-p53 antibody clone D0-7 which detects both wild-type and
the mutant p53 variant (Figure 4A). p53, in the setting of DNA
damage, induces p21 expression at the transcriptional level. p53
expression was detected in four of six BL and five of eight DLBCL
tumors (Figure 4A). However, inactivating mutations in p53 occurs
in up to 60% of AIDS-BL [36] and 40% of AIDS-DLBCL [37]
often leading to enhanced p53 protein stability and its accumu-
lation in tumors [38]. Therefore, it is likely that we are detecting
mutant p53, which is unable to act as a transcription factor, thus
having no effect on p21 transcription. Overall, due to the lack of
p21 protein detection we are unable to show an inverse correlation
between these miRNAs and p21 protein expression. However,
given the p21 mRNA expression in these tumors, it is clear that
miRNA-17 family members (including miR-17, miR-106a, miR-
106b) play a significant role in inhibiting p21 protein expression in
AIDS-NHLs.
Discussion
Recently, it has become increasingly clear that miRNAs play a
significant role in B cell tumorigenesis, especially those encoded by
the miR-17-92 polycistron. However, the role of miRNAs in NHL
in the setting of HIV/AIDS has only begun to be appreciated.
Previous studies have found downregulation of the tumor
suppressor miRNAs, miR-221, miR-222, and let-7 in PEL lines
[39,40], and targeting of the T-cell attracting chemokine CXCL-
11 by EBV miRNA BHRF1-3 in primary AIDS tumors [41]. In
this report, we used primary AIDS-NHL tumors and investigated
whether miRNAs from the miR-17-92 cluster and its paralogs
were also associated with AIDS-NHLs pathogenesis.
First, in order to establish a differentiation specific role for
miRNA in normal B cell maturation, we assessed the miRNA
profile of naı ¨ve, GC, and memory B cells isolated from tonsils. We
and others [42–44] have shown that these B cell subsets exhibit a
distinct miRNA signature. Many of the miRNAs that are
dynamically regulated as the cells progress through the GC
reaction have been shown to target transcription factors and key
regulators of cell proliferation and apoptosis. miR-223, which is
downregulated during the naı ¨ve to GC transition, targets the GC
expressed transcription factors LMO2 [42,43] and MYBL1 [43].
miR-150, downregulated in GC subsets, targets c-Myb and
survivin [44]. miR-30c and miR-30e are downregulated in GC
when its target, the GC specific Bcl6 is expressed [45]. And let-7a,
which is expressed only in the naı ¨ve subset, targets PRDM1/
Blimp-1 [46], which is a key regulator of post GC differentiation
into plasma cells. Finally, we show that miRNA members from the
miR-17-92 paralog clusters (miR-17, miR-18a, miR-18b, miR-
19a, miR-19b, miR-20a, miR-20b, miR-106a, and miR-106b) are
tightly controlled in normal B cells, with increased expression seen
only during naı ¨ve to GC transition and immediate downregulation
upon GC exit (Figure 1A).
The oncogenic role for the miR-17-92 polycistron in B cell
NHL has been well established [19–23,30]. Gene duplication
events of the miR-17-92 cluster (chromosome 13) gave rise to its
paralogs, miR-106a-363 (chromosome X), and miR-106b-25
(chromosome 7) (Figure 1B). We find that miRNAs from all three
clusters, miR-17, miR-18a, miR-19a from miR-17-92 cluster;
miR-106a from miR-106a-363 cluster; and miR-106b from
miR106b-25 cluster, are overexpressed in various AIDS-NHLs
including, BL, DLBCL, PCNSL, and PEL types. miRNA
members from this paralog clusters have been shown to target
Figure 2. miRNAs from miR-17-92, miR-106a-363, and miR-106b-25 paralogous clusters are overexpressed in AIDS-NHLs. Taqman
q-PCR assessed relative levels of (A) miR-17, (B) miR-106a, (C) miR-106b, (D) miR-18a, and (E) miR-19a in AIDS related BL, DLBCL, CNS, PEL compared
to B cells from PBMC and tonsils. The expression of miRNAs was normalized to the expression of RNU48. Table S2 summarizes the Y-axis values used
in these plots. Horizontal line through sample cluster represents the median value for each group. The median of each tumor group was compared to
the combined median of the non-tumor group (PBMC and tonsil). P values were calculated using two-tailed Mann-Whitney U test (* signifies p,0.05
and ** signifies p,0.01). BL, Burkitt’s lymphoma; DLBCL, diffuse large B-cell lymphoma; CNS, primary central nervous system lymphoma; PEL, primary
effusion lymphoma.
doi:10.1371/journal.pone.0020781.g002
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5p and miR-20a target cyclin D1 [47]; miR-25 targets Bim [48]
and p57 [49]; miR-17 and miR-20 target E2F1 [50]; miR-19a
targets PTEN [51]; and miRNAs-17, miR-20, miR-106b, and
miR-93 target p21 [27,28,48,52]. Recently, p21 was also shown to
be targeted by the PEL associated herpesvirus HHV-8 miR-K1
[53]. p21 is a cyclin dependent kinase inhibitor that blocks G1 to S
cell cycle progression. Our results show that the miR-17 family
mediated suppression of p21 is also a common feature in AIDS-
NHL. It is appropriate that miRNAs specifically upregulated
during the GC stage target negative regulators of cell cycle
progression. Rapid proliferation is a hallmark of GC B cells and is
required for the generation of highly antigen specific plasma and
memory cells. We hypothesize that the inability of normal B cells
to turn off expression of miR-17-92 and its paralogs upon GC exit
may be a factor in the pathogenesis of these mature B cell cancers.
Several studies have looked at the transcriptional regulation of
the miR-17-92 cluster. c-Myc, the proto-oncogene activated in
most BL, has been shown to be a transcription factor for the miR-
17-92 polycistron [54]. c-Myc was also shown to have a
significantly higher transcriptional activity in DLBCL tumor
subsets overexpressing the miR-17-92 cluster miRNAs [55].
However, c-Myc is downregulated in centroblastic B cells in the
germinal center [56] arguing for a distinct mechanism of miR-17-
Figure 4. p21 protein and RNA expression in primary AIDS-NHL samples. (A) p21 Western blot analysis of primary AIDS- BL and AIDS-DLBCL
samples. The blot was stripped and sequentially probed for p53 (Ab clone DO-7) and b-actin. No p21 protein expression was detected. The positive
control is lysate from p21 cDNA transfected B cell line Ramos. (B) Taqman q-PCR of p21 mRNA levels in primary AIDS-NHL samples shown in A. In
each sample, p21 mRNA level is shown as a % of b-actin expression, which is set to 100.
doi:10.1371/journal.pone.0020781.g004
Figure 3. miR-17 family members target p21/CDKN1A. (A) Schematic of the 39UTR of p21 showing the two locations in the 39UTR targeted by
miR-17 family. Boxed region shows the miRNA seed sequence common to this family. Mutations made in the p21 39UTR construct that was cloned
into p-MIR-REPORT vector is also shown. (B) p21-39UTR firefly/renilla luciferase reporter activity in 293T cells cotransfected with precursor miRNAs.
premiR-106a (*, p=0.03) and premiR-106b (**, p=0.01) showed significant downregulation of luciferase activity when wt p21-UTR was compared to
p21-UTR mutant. Error bars represent the mean +/2 SD of three independent experiments. Relative luciferase=Firefly luciferase (39UTR)/Renilla
luciferase (transfection control). (C) Representative Western blot of Toledo cells 3 day post transfection with antimiRs-17, -106a, -106b. Numbers
represent fold change in p21 protein density (normalized to b-actin). antimiR-control transfected lane value was set to 1. The membrane was stripped
and reprobed sequentially for Bcl2, Bim, CDK 4/6, and b-actin. (D) Taqman q-PCR of p21 mRNA levels normalized to b-actin in Toledo cells transfected
as in C. Error bars represent mean +/2 SD of three independent experiments. (E, F) 2F7 and Toledo cells were transfected with precursors or antimiRs
(respectively) for miR-17, miR-106a, and miR-106b along with scrambled controls. XTT cell proliferation assay was done at 24 hr intervals post
transfection. Proliferation of cells were standardized to the proliferation of control pre/antimiR transfected cells at 48 hrs, which was set to 100%.
Error bars represent the mean +/2 SD of three independent experiments. * signifies p,0.05 for miR-106b when compared to control proliferation.
doi:10.1371/journal.pone.0020781.g003
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tumors. E2F1 and E2F3, belonging to the E2F family of
transcription factors required for cell cycle progression, have also
been shown to activate miR-17-92 transcription [57]. And under
hypoxic conditions, p53 directly competes with the TATA-binding
protein (TBP) transcription factor binding to the promoter of miR-
17-92, thus inhibiting its expression [58]. The precise mechanism
by which these and other factors control transcription of miR-17-
92 and its paralogs, leading to its dysregulation in various
lymphoma subtypes, remain to be answered.
Finally, in addition to elucidating molecular roles for miRNAs
in tumor pathogenesis, the possible utility of miRNAs as diagnostic
and prognostic biomarkers cannot be overlooked, especially as
these miRNAs can be detected in body fluids, which can be
obtained by less invasive means than are required to obtain tumor
biopsy specimens. Lawrie et al. reported the expression of miR-
155, miR-210, and miR-21 in serum from DLBCL patients and
found association of high miR-21 expression with relapse-free
survival [59]. More recently, miR-21, and two members of the
miR-17-92 cluster, miR-19 and miR-92a, were found to be
elevated in the cerebrospinal fluid (CSF) of PCNSL patients [60].
This is in agreement with our results, which show overexpression
of miR-17-92 paralog clusters in PCNSL tumors.
In conclusion, we show that miRNAs from the miR-17-92
cluster and its paralogs are overexpressed in various AIDS-NHL
subtypes and provide evidence that these miRNAs contribute to
the pathogenesis of these tumors by suppression of p21. Future
studies looking at tumor deregulated miRNAs and its presence in
relatively accessible body fluids should enhance the early
detection, differential diagnosis, and prognosis of various B
lymphoma subtypes.
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